iBio, Inc. 

iBio, Inc. (NYSE: IBIO) is a biopharmaceutical developer and the inventor of the sustainable FastPharming Manufacturing System. Using licensed and owned technologies, the company develops novel treatments to prevent fibrotic disorders, malignancies, and infectious diseases. 

Key Highlights: 

• The company reported a significant decline in revenues to USD 211 thousand in Q1FY22 (ended September 30, 2021) compared to USD 410 thousand in Q1FY21. 
• IBIO generated 100%of its revenue from three clients in Q1FY22, with two customers accounting for 81%of revenue; losing any customer could negatively influence the company's topline in the future. 
• IBIO reported an increase in net losses to USD 8.94 million in Q1FY22 from USD 7.53 million in Q1FY21. 
• In Q1FY22, the company's average receivable days were 2,336 days, compared to the industry median of 60.5 days. 
• The stock is now trading below its key short-term (50-day) and long-term (200-day) DMA support levels, with the RSI Index at 36.66, indicating a bearish trend. 

• Stock is leaning towards the lower band of the 52-week range of USD 0.39 to USD 2.83. 
• IBIO stock price has fallen 66.38and 72.24% inthe past six and nine months, respectively. 

Three-Year Technical Price Chart (as of February 10, 2022; 12:33 PM ET). Analysis by Kalkine Group 

Conclusion: Considering the bottom-line stress, uncertain outlook, insignificant topline, reliance on specific customers, and other technical indicators, we recommend an "Avoid" rating on the stock at the current price of USD 0.4136, down 1.52% as of February 10, 2022, at 12:33 PM ET. 

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer 

References to ‘Kalkine’, ‘we’, ‘our’ and ‘us’ refer to Kalkine Limited. 

This website is a service of Kalkine Limited. Kalkine Limited is a private limited company, incorporated in England and Wales with registration number 07903332. Kalkine Limited is authorised and regulated by the Financial Conduct Authority under reference number 579414. 

The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. No advice or information, whether oral or written, obtained by you from Kalkine or through or from the service shall create any warranty not expressly stated. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation.  

Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall NOT be held liable for any investment or trading losses you may incur by using the opinions expressed in our publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested. 

Kalkine Media Limited, an affiliate of Kalkine Limited, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.